May/June 2013 Vol 6, No 4
I had the recent privilege of carrying the “flags” of our school and of American Health & Drug Benefits to the enchanting island of Japan as a plenary speaker at the 113th Annual Congress of the Japanese Surgical Society. I would like to share some of my reflections on this incredibly complicated, and sometimes even paradoxical, medical culture during my 1-week whirlwind visit.
Abby Swanson Kazley, PhD, Kit N. Simpson, DrPH, Annie Simpson, PhD, Edward Jauch, MD, Robert J. Adams, MD
Stroke remains a leading cause of disability and is the fourth leading cause of death in the United States.1,2 Approximately 780,000 strokes occur in the United States annually; in 2004, stroke accounted for 1 of every 16 deaths.3 The burden of stroke is especially high in South Carolina, which is central within the so-called Stroke Belt.4-7 The Stroke Belt is an 11-state region in the southeastern United States that has been characterized as having a particularly high incidence of stroke.
Stroking This South Carolina Model: Will It Play in Peoria?
Christopher Hvisdas, PharmD Candidate, Andrea Lordan, PharmD Candidate, Laura T. Pizzi, PharmD, MPH, Brandi N. Thoma, PharmD
In recent years, drug shortages have become a common occurrence in hospital and retail settings, with a record high of 267 drug shortages reported in 2011.1 Julie A.
Drug Shortages in the United States Continue to Undermine Patient Care
Step-Up Therapy Program for Anti-Inflammatory Biologic Agents Does Not Increase Cost Nor Adversely Affect Patient Outcomes
The step therapy requirement for adalimumab coverage does not lead to increased cost to the health plan or increased utilization, according to a retrospective claims-based study by Kyle Burcher, PharmD, UnitedHealthcare Pharmacy, Minnetonka, MN, and colleagues from UnitedHealthcare and OptumInsight. They presented their data at the 2013 annual meeting of the Academy of Managed Care Pharmacy.1
Jacqueline Pesa, PhD, MPH, Roxanne Meyer, PharmD, Tiffany P. Quock, PhD, MS, Stacy K. Rattana, RN, BSN, Samir H. Mody, PharmD, MBA
Diabetic peripheral neuropathy (DPN) is one of the most common complications associated with diabetes, occurring in 30% to 50% of patients with type 2 diabetes and affecting approximately 1 million Americans annually.1,2 DPN manifests as spontaneous painful, burning, electric, or shooting sensations in the extremities, with 10% to 20% of patients with DPN experiencing moderate-to-severe pain.3-6 Of these patients, 11% to 26% develop chronic pain, which is defined as pain that continues for an extended period of time that may be associated with a recognizable disease process.
Monitoring for Aberrant Opioid Utilization Patterns a Growing Need in Managed Care
The following summaries of posters presented at the 2013 Annual Meeting of the Academy of Managed Care Pharmacy (AMCP), April 3-5, 2013, in San Diego, CA, represent areas of interest for payers, employers, drug manufacturers, providers, and other healthcare stakeholders.
An Inside Look at Managed Care Executive Conversations within the Health Payer Council: What Is Evidence?
In 2010, the payer landscape was changing rapidly, with no central place for medical and pharmacy directors to exchange ideas and to expand the ways in which they viewed the ever more complex daily choices and decisions with which they were faced. In addition, there are challenges regarding speaking one’s mind publicly. Some payer organizations chastise their directors for giving their personal opinions in any setting, claiming that everything the director says reflects on the company as a whole.
Results 1 - 8 of 8